Brandenburg VM, d'Haese P, Deck A et al. From skeletal to cardiovascular disease in 12 steps: the evolution of sclerostin as a major player in CKD-MBD. Pediatr Nephrol (advance online publication 4 March 2015; doi: 10.1007/s00467-015-3069-7)
Robling AG, Niziolek PJ, Baldridge LA et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of sost/sclerostin. J Biol Chem 2008; 283: 5866-5875
de Oliveira RA, Barreto FC, Mendes M et al. Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. Kidney Int 2015; 87: 1039-1045
Delanaye P, Krzesinski JM, Warling X et al. Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract 2014; 128: 127-134
Cejka D, Herberth J, Branscum AJ et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877-882
Cejka D, Jager-Lansky A, Kieweg H et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012; 27: 226-230
Malluche HH, Davenport DL, Cantor T et al. Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis. Clin J Am Soc Nephrol 2014; 9: 1254-1262
Qureshi AR, Olauson H, Witasp A et al. Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int 2015; 88: 1356-1364
Durosier C, van Lierop A, Ferrari S et al. Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab 2013; 98: 3873-3883.